Wall Street analysts forecast that Alpine Immune Sciences Inc (NASDAQ:ALPN) will report sales of $290,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Alpine Immune Sciences’ earnings. The lowest sales estimate is $250,000.00 and the highest is $320,000.00. Alpine Immune Sciences posted sales of $320,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 9.4%. The firm is scheduled to announce its next earnings results on Monday, May 13th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full-year sales of $1.13 million for the current fiscal year, with estimates ranging from $1.00 million to $1.26 million. For the next financial year, analysts expect that the company will report sales of $1.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.80).

Several brokerages have commented on ALPN. Zacks Investment Research downgraded shares of Alpine Immune Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, March 21st. Oppenheimer set a $13.00 price objective on shares of Alpine Immune Sciences and gave the company a “buy” rating in a research report on Tuesday, March 19th. ValuEngine downgraded shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Friday, January 11th. Finally, restated a “buy” rating and set a $13.00 price objective on shares of Alpine Immune Sciences in a research report on Tuesday, February 12th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $12.07.

ALPN traded down $0.45 during trading on Tuesday, hitting $6.75. 23,570 shares of the stock traded hands, compared to its average volume of 15,783. Alpine Immune Sciences has a twelve month low of $3.66 and a twelve month high of $10.57. The company has a market cap of $99.75 million, a P/E ratio of -2.57 and a beta of 2.13. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.59 and a quick ratio of 6.59.

In other news, major shareholder Tiger Management L.L.C. sold 25,000 shares of the company’s stock in a transaction on Friday, February 8th. The shares were sold at an average price of $5.85, for a total transaction of $146,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 69.00% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in ALPN. Hikari Power Ltd acquired a new position in shares of Alpine Immune Sciences during the fourth quarter worth $453,000. Victory Capital Management Inc. increased its holdings in shares of Alpine Immune Sciences by 109.0% during the fourth quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after buying an additional 70,980 shares in the last quarter. Vanguard Group Inc increased its holdings in shares of Alpine Immune Sciences by 5.2% during the third quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Alpine Immune Sciences by 5.2% during the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares in the last quarter. Institutional investors own 53.79% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Further Reading: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.